Kineta has received an undisclosed investment sum from the Iacocca Family Foundation to advance the development of ShK-186, its drug candidate for autoimmune diseases such as Type 1 diabetes and multiple sclerosis. The Seattle-based biotech firm plans to conduct a Phase I trial of the drug, which inhibits some of the white blood cells that activate inflammation in autoimmune conditions, later this year.

Full Story:
The Seattle Times

Related Summaries